Key result
Elevated NT-proBNP is linked to ~77% greater odds of poor 3-month prognosis after stroke thrombolysis.
Why the study?
Few studies have correlated NT-proBNP with early neurological deterioration and prognosis in acute ischaemic stroke patients receiving rt-PA intravenous thrombolysis.
Does elevated NT-proBNP predict early neurological deterioration and poor prognosis in patients with acute ischemic stroke after intravenous thrombolysis?
Observational (n=325)
No
Does elevated NT-proBNP predict early neurological deterioration and poor prognosis in patients with acute ischemic stroke after intravenous thrombolysis?
Effect estimate: OR 1.767 (95% CI 1.347-2.317)
p-value: p=<0.001
Elevated baseline NT-proBNP is an independent predictor of early neurological deterioration and poor 3-month functional prognosis in patients with acute ischemic stroke treated with intravenous thrombolysis.
OBJECTIVE: Few studies correlated n-terminal pro-brain natriuretic peptide (NT-proBNP) with early neurological deterioration (END) and prognosis of acute ischaemic stroke (AIS) patients with rt-PA intravenous thrombolysis. Therefore this study aimed to investigate the relationship between NT-proBNP and END, and prognosis after intravenous thrombolysis in patients with AIS. METHODS: A total of 325 patients with AIS were enrolled. We performed the natural logarithm transformation on the NT-proBNP [ln(NT-proBNP)]. Univariate and multivariate logistic regression analyses were performed to assess the relationship between ln(NT-proBNP) and END, and prognosis and receiver operating characteristic (ROC) curves were used to show the sensitivity and specificity of NT-proBNP. RESULTS: After thrombolysis, among 325 patients with AIS, 43 patients (13.2%) developed END. In addition, three months follow-up showed a poor prognosis in 98 cases (30.2%) and a good prognosis in 227 cases (69.8%). Multivariate logistic regression analysis showed that ln(NT-proBNP) was an independent risk factor for END (OR = 1.450,95%CI:1.072 ~ 1.963, P = 0.016) and poor prognosis at three months follow-up (OR = 1.767, 95%CI: 1.347 ~ 2.317, P < 0.001) respectively. According to ROC curve analysis, ln(NT-proBNP) (AUC 0.735, 95%CI: 0.674 ~0.796, P < 0.001) had a good predictive value for poor prognosis, with a predictive value of 5.12 and sensitivity and specificity of 79.59% and 60.35% respectively. When combined with NIHSS to predict END(AUC 0.718, 95%CI: 0.631 ~ 0.805, P < 0.001) and poor prognosis(AUC 0.780, 95%CI: 0.724 ~ 0.836, P < 0.001), the predictive value of the model is further improved. CONCLUSION: NT-proBNP is independently associated with END and poor prognosis in patients with AIS following intravenous thrombolysis and has a particular predictive value for END and poor prognosis.
No takes yet. Share an insight, caveat, or question.
Zhu et al. (2023) conducted an observational in Acute ischemic stroke (n=325). Elevated NT-proBNP vs. Lower NT-proBNP was evaluated on Poor prognosis at 3 months (mRS ≥ 3) (OR 1.767, 95% CI 1.347-2.317, p=<0.001). Elevated ln(NT-proBNP) was an independent risk factor for poor prognosis at three months (OR 1.767) in patients with acute ischemic stroke following intravenous thrombolysis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: